DK1682131T3 - CCI-779 til behandling af mantle-cellelymfom - Google Patents

CCI-779 til behandling af mantle-cellelymfom

Info

Publication number
DK1682131T3
DK1682131T3 DK04796697T DK04796697T DK1682131T3 DK 1682131 T3 DK1682131 T3 DK 1682131T3 DK 04796697 T DK04796697 T DK 04796697T DK 04796697 T DK04796697 T DK 04796697T DK 1682131 T3 DK1682131 T3 DK 1682131T3
Authority
DK
Denmark
Prior art keywords
cci
treatment
cell lymphoma
mantle cell
mantle
Prior art date
Application number
DK04796697T
Other languages
Danish (da)
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1682131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of DK1682131T3 publication Critical patent/DK1682131T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
DK04796697T 2003-11-04 2004-10-28 CCI-779 til behandling af mantle-cellelymfom DK1682131T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04
PCT/US2004/035900 WO2005046681A1 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma

Publications (1)

Publication Number Publication Date
DK1682131T3 true DK1682131T3 (da) 2008-01-28

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04796697T DK1682131T3 (da) 2003-11-04 2004-10-28 CCI-779 til behandling af mantle-cellelymfom

Country Status (31)

Country Link
US (2) US20050113403A1 (de)
EP (1) EP1682131B9 (de)
JP (1) JP4856548B2 (de)
KR (1) KR101387988B1 (de)
CN (1) CN1901906B (de)
AR (1) AR046194A1 (de)
AT (1) ATE373477T1 (de)
AU (1) AU2004289213B2 (de)
BR (1) BRPI0415714A (de)
CA (1) CA2543665C (de)
CO (1) CO5690605A2 (de)
CR (1) CR8383A (de)
DE (1) DE602004009098T2 (de)
DK (1) DK1682131T3 (de)
EC (1) ECSP066600A (de)
ES (1) ES2291954T3 (de)
GT (1) GT200400224A (de)
HK (1) HK1088241A1 (de)
IL (2) IL175128A0 (de)
MY (1) MY136436A (de)
NO (1) NO20062271L (de)
PA (1) PA8616601A1 (de)
PE (1) PE20051000A1 (de)
PL (1) PL1682131T3 (de)
PT (1) PT1682131E (de)
RU (1) RU2358731C2 (de)
SA (1) SA04250375B1 (de)
TW (1) TW200517116A (de)
UA (1) UA83697C2 (de)
WO (1) WO2005046681A1 (de)
ZA (1) ZA200603533B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20080207644A1 (en) * 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
MXPA03010907A (es) 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EA008379B1 (ru) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
ATE385795T1 (de) * 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
DK1615640T3 (da) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastiske sammensætninger
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
US20050113403A1 (en) 2005-05-26
UA83697C2 (ru) 2008-08-11
EP1682131B9 (de) 2009-03-25
SA04250375B1 (ar) 2007-08-13
CN1901906B (zh) 2011-11-16
IL220080A0 (en) 2012-07-31
AR046194A1 (es) 2005-11-30
WO2005046681A1 (en) 2005-05-26
BRPI0415714A (pt) 2006-12-19
PA8616601A1 (es) 2006-06-02
NO20062271L (no) 2006-07-21
AU2004289213B2 (en) 2010-08-26
RU2358731C2 (ru) 2009-06-20
US8507518B2 (en) 2013-08-13
RU2006119451A (ru) 2007-12-20
CA2543665C (en) 2009-07-14
US20110184010A1 (en) 2011-07-28
PE20051000A1 (es) 2006-02-03
EP1682131B1 (de) 2007-09-19
ZA200603533B (en) 2007-07-25
DE602004009098T2 (de) 2008-06-26
HK1088241A1 (en) 2006-11-03
IL175128A0 (en) 2008-04-13
DE602004009098D1 (de) 2007-10-31
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
JP4856548B2 (ja) 2012-01-18
CR8383A (es) 2006-10-04
CO5690605A2 (es) 2006-10-31
ATE373477T1 (de) 2007-10-15
CN1901906A (zh) 2007-01-24
AU2004289213A1 (en) 2005-05-26
ECSP066600A (es) 2006-10-25
TW200517116A (en) 2005-06-01
KR20060111559A (ko) 2006-10-27
PT1682131E (pt) 2007-11-08
ES2291954T3 (es) 2008-03-01
JP2007510721A (ja) 2007-04-26
EP1682131A1 (de) 2006-07-26
GT200400224A (es) 2005-06-06
KR101387988B1 (ko) 2014-04-22
CA2543665A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
NO20034941D0 (no) Renseanlegg for varmekraftverk
DK2959774T3 (da) Fremgangsmåde til kryokonservering af sædceller
DK1897548T4 (da) T-celleregulering
ATE389374T1 (de) Zwischenwirbelimplantat
DK1647529T3 (da) Fremgangsmåde til oprensing af spildevand
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DE60207518D1 (de) Dämpfungseinrichtung
SE0303324L (sv) Implantat
DK1516596T3 (da) Forbedret system til behandling af stress-urinkontinens
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
IL220080A0 (en) Cci-779 for treating mantle cell lymphoma
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
DE502004008433D1 (de) Wägezelle
SE0303322L (sv) Implantat
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
NO20053428D0 (no) Fremgangsmate for dermal beskyttelse.
FR2853526B1 (fr) Support de biberon
DK1636140T3 (da) Mindre enhed til behandling af spildevand
DE502004006756D1 (de) Zellbehandlungskammer